Biosimilar User Fees Could Be Raised Significantly In Renewal Talks
Executive Summary
Workload is not what was expected when BsUFA was designed, FDA says.
You may also be interested in...
Biosimilar User Fees Discounted To Begin Second Round
After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.
Biosimilar User Fees Discounted To Begin Second Round
After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.
Biosimilar Suffix Detractors Hope Private Studies Build Their Case
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.